Siren Biotechnology Receives FDA Clearance for First AAV-Based Cancer Gene Therapy IND
Key Insights
Siren Biotechnology (search) received FDA clearance for its first Investigational New Drug application, marking the company's transition to clinical-stage development.
The IND supports evaluation of the company's Universal AAV Immuno-Gene Therapy (search) platform in adult patients with recurrent high-grade glioma.
This represents what Siren believes is the first FDA-cleared IND for an adeno-associated virus-based therapy in an oncology indication.
Siren Biotechnology (search) announced that the U.S. Food and Drug Administration has cleared the company's first Investigational New Drug application, enabling initiation of its first-in-human clinical trial and officially advancing the San Francisco-based company to clinical-stage status. The IND clearance supports evaluation of Siren's lead investigational program in adult patients with recurrent high-grade glioma.
The regulatory milestone represents what Siren believes is the first FDA-cleared IND for an adeno-associated virus-based therapy in an oncology indication, underscoring the growing potential of gene therapy approaches in cancer treatment.
Novel AAV-Based Platform Targets Aggressive Brain Tumors
"This IND clearance represents a defining moment for Siren as we transition from a preclinical-stage company into the clinic," said Nicole K. Paulk, PhD, Founder, CEO, and President of Siren Biotechnology (search). "Reaching this milestone reflects years of focused platform development, rigorous translational work, and close engagement with regulators, and it positions us to begin evaluating our approach in patients."
The company's Universal AAV Immuno-Gene Therapy (search) platform combines the precision and durability of AAV gene therapy with immune-modulating potential of cytokine-based approaches. The platform is designed to enable localized and durable delivery of immune-modulating payloads directly within tumors, supporting sustained immune activation across solid tumors.
Addressing Critical Unmet Medical Need
High-grade gliomas, including glioblastoma, are among the most aggressive and lethal primary brain tumors. Current treatments include surgery, radiation, and chemotherapy, all of which offer limited benefit, creating an urgent need for novel therapeutic approaches.
The IND clearance follows the FDA's prior granting of Orphan Drug and Rare Pediatric Disease designations for the program, reflecting the significant unmet medical need in this patient population. The regulatory approval reflects completion of nonclinical and chemistry, manufacturing, and controls activities required to support clinical evaluation.
California Funding Supports Innovation
The research was made possible through funding from the California Institute for Regenerative Medicine (search), a state agency that funds regenerative medicine, stem cell, and gene therapy research. CIRM, created by California voters and supported by $8.5 billion in funding through Proposition 71 in 2004 and Proposition 14 in 2020, supports discoveries from inception through clinical trials while building California's biotech workforce and clinical trial infrastructure.
Siren plans to initiate the first-in-human clinical study in adult patients with recurrent high-grade glioma, building on the company's broader platform designed to support localized, sustained immune activation across solid tumors.